Summit Therapeutics Inc. (SMMT)
Summit Therapeutics Inc.
601 Brickell Key Drive
Suite 1000
Miami, FL 33131
United States
650 460 8308
https://www.summittxinc.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 105
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Robert W. Duggan | Co-CEO & Executive Chairman | N/D | N/D | 1945 |
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director | 657.81k | N/D | 1970 |
| Mr. Manmeet Singh Soni | COO, CFO & Director | 591.5k | N/D | 1978 |
| Prof. Dame Kay Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | N/D | N/D | 1951 |
| Mr. Bhaskar Anand | Chief Accounting Officer & Head of Finance | N/D | N/D | 1978 |
| Ms. Abby Guzman Murphy | Head of Human Resources | N/D | N/D | N/D |
| Ms. Divya Chari | Head of Global Clinical Operations | N/D | N/D | 1968 |
| Mr. Dave Gancarz | Chief Business & Strategy Officer? | N/D | N/D | N/D |
| Mr. Will Black | Head of Information Technology? | N/D | N/D | N/D |
| Dr. Betty Y. Chang Ph.D. | Head of Research, Oncology & Inflammation? | N/D | N/D | N/D |
Descripción
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.
Gestión corporativa
La calificación ISS Governance QuickScore de Summit Therapeutics Inc. a partir del 29 de abril de 2024 es 8. Las puntuaciones principales son Auditoría: 9; Junta: 9; Derechos del accionista: 5; Compensación: 7.
